La vendita allo scoperto per Apellis Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Apellis Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Apellis Pharmaceuticals (NASDAQ:APLS) Azioni, Report sulle vendite allo scoperto

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals Inc

Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $45.35, a high estimate of $92.00, and a low estimate of $24.00. A 23.06% drop is evident in the current average compared to the previous average price target of $58.94. 
<img src="https://www.benzinga.com/files/images/story/2024/1732190409_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$57.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Apellis Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Apellis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Key Indicators: Apellis Pharmaceuticals's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 78.29% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -29.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -22.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.36%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.98, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

APLS

A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

News

Price Target

Initiation

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

U.S. stocks were lower, with the Dow Jones index falling more than 350 points on Tuesday.
Shares of Energizer Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/ENR/earnings">better-than-expected quarterly earnings.</a>
Energizer reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.17 per share. The company reported quarterly sales of $805.70 million which missed the analyst consensus estimate of $806.4 million.
Energizer shares jumped 12.8% to $38.52 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares jumped 31.9% to $28.41 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) gained 26.5% to $38.66 after the company on Monday reported better-than-expected quarterly financial results.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares rose 17% to $2.0600.</li>
<li>Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares jumped 16.2% to $10.04.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) surged 15.4% to $30.20.</li>
<li>C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares rose 14.3% to $30.33 after the company announced a strategic alliance with Microsoft to accelerate the adoption of enterprise AI on Azure.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) surged 12.7% to $38.93</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) rose 11.6% to $8.65.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) gained 11.5% to $17.82.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 10% to $12.84.</li>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) surged 7.7% to $71.73. Insmed, on Nov. 18, terminated sales agreement with Leerink Partners.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares rose 7.1% to $6.01. Needham analyst Chris Pierce initiated coverage on Joby Aviation with a Buy rating and announced a price target of $8.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 5.5% to $21.83.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42060660/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

ALMS

APLD

BBAI

INSM

JOBY

LMND

LUNR

OKLO

OSCR

SMCI

Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $92 to $55.

Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $55

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $63 to $51.

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $51

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $71 to $36.

Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $36

RBC Capital analyst Luca Issi maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $25 to $24.

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24

Scotiabank analyst Greg Harrison maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $35 to $30.

Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $30

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and lowers the price target from $43 to $30.

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $30

Oppenheimer analyst Justin Kim maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $65 to $40.

Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $40

Piper Sandler analyst Biren Amin maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $40 to $32.

Piper Sandler Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $32

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham cut Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) price target from $85 to $60. Needham analyst Joseph Stringer maintained a Buy rating. Apellis Pharmaceuticals shares closed at $28.08 on Tuesday. See how other analysts view this stock.</li>
<li>Deutsche Bank raised the price target for Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) from $136 to $140. Deutsche Bank analyst Nicole Deblase maintained a Buy rating. Emerson Electric shares closed at $117.67 on Tuesday. <a href="https://www.benzinga.com/quote/EMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised the price target for Arcellx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) from $80 to $95. HC Wainwright &amp; Co. analyst Emily Bodnar maintained a Buy rating. Arcellx shares closed at $87.12 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley slashed NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) price target from $250 to $235. Morgan Stanley analyst Joseph Moore maintained an Equal-Weight rating. NXP Semiconductors shares settled at $224.65 on Tuesday. <a href="https://www.benzinga.com/quote/NXPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Freshpet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) price target from $155 to $165. Stifel analyst Mark Astrachan maintained a Buy rating. Freshpet shares closed at $151.59 on Tuesday. <a href="https://www.benzinga.com/quote/FRPT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird increased Choice Hotels International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) price target from $138 to $145. Baird analyst Michael Bellisario maintained an Outperform rating. Choice Hotels shares closed at $139.46 on Tuesday. <a href="https://www.benzinga.com/quote/CHH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from $350 to $380. Baird analyst Mark Altschwager maintained an Outperform rating. Lululemon shares settled at $319.23 on Tuesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised Broadridge Financial Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) price target from $200 to $207. Morgan Stanley analyst James Faucette maintained an Equal-Weight rating. Broadridge Financial shares closed at $218.30 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Cummins Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NASDAQ">CMI</a>) from $330 to $372. Baird analyst David Leiker maintained a Neutral rating. Cummins shares closed at $354.46 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) price target from $133 to $173. Truist Securities analyst Jamie Cook upgraded the stock from Hold to Buy. Lionsgate Studios shares closed at $6.76 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Pre-Market Outlook

ACLX

FRPT

LION

LULU

NXPI

Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $83 to $57.

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $57

B of A Securities analyst Tazeen Ahmad maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $61 to $47.

B of A Securities Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $47

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $85 to $60.

Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

WIIM

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its quarterly dividend.
Celanese reported quarterly earnings of $2.44 per share which missed the analyst consensus estimate of $2.85 per share. The company reported quarterly sales of $2.65 billion which missed the analyst consensus estimate of $2.70 billion.
Celanese shares dipped 15.8% to $103.89 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 19.4% to $2.10 in pre-market trading after the company reported weak third-quarter sales.</li>
<li>JELD-WEN Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) shares declined 18.5% to $11.51 in pre-market trading after the company reported downbeat quarterly results and lowered FY24 sales forecast.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) declined 18% to $42.55 in pre-market trading following soft fourth-quarter guidance.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) fell 14.3% to $2.22 in pre-market trading after the company reported weak third-quarter financial results.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) declined 13% to $13.99 in pre-market trading.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) fell 10.3% to $13.55 in pre-market trading after the company posted weak quarterly sales and lowered FY24 sales forecast.</li>
<li>Cirrus Logic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) shares fell 9.7% to $99.83 in pre-market trading following second-quarter results.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) dipped 9.5% to $25.84 in pre-market trading following weak quarterly results.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) shares fell 6.5% to $12.26 in pre-market trading following downbeat third-quarter results.</li>
<li>Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) shares declined 5.6% to $31.51 in pre-market trading after reporting third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

ATUS

CRUS

JELD

LSCC

NVTS

TCMD

Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Biotech

Earnings

Health Care

General

Apellis Pharmaceuticals Reports Cash And Cash Equivalents Of $396.9M As Of September 30, 2024; Projected Revenues And Cash Expected To Be Sufficient To Fund Operations To Positive Cash Flow

Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.30) by 53.33 percent. This is a 60.68 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $196.83 million which missed the analyst consensus estimate of $200.35 million by 1.76 percent. This is a 78.29 percent increase over sales of $110.40 million the same period last year.

Apellis Pharmaceuticals Q3 2024 GAAP EPS $(0.46) Misses $(0.30) Estimate, Sales $196.83M Miss $200.35M Estimate

<h3>Gainers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares moved upwards by 115.4% to $0.41 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.4 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares increased by 12.37% to $2.09. The company's market cap stands at $21.2 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) stock moved upwards by 12.09% to $0.66. The market value of their outstanding shares is at $14.1 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock increased by 10.38% to $2.91. The market value of their outstanding shares is at $7.3 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares increased by 9.73% to $0.08. The company's market cap stands at $1.3 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock moved upwards by 8.86% to $22.6. The company's market cap stands at $4.8 billion. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) stock declined by 32.2% to $0.97 during Tuesday's pre-market session. The company's market cap stands at $41.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) shares declined by 14.43% to $12.93. The company's market cap stands at $309.8 million. The company's, Q3 earnings came out yesterday. </li>
<li>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) stock declined by 11.77% to $25.2. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares fell 10.63% to $1.85. The company's market cap stands at $2.5 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares decreased by 10.26% to $1.75. The market value of their outstanding shares is at $3.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 8.51% to $0.23. The company's market cap stands at $3.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

BNOX

COCP

CYCN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LIXT

SLXN

TOVX

VRCA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Jefferies analyst Akash Tewari maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of $57.00. ...

Apellis Pharmaceuticals (APLS) Receives a Buy from Jefferies

Astellas receives Complete Response Letter from FDA for Izervay sNDA

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Walmart (WMT) provided a "beat and rai...

Walmart higher, Lowe's lower after earnings: Morning Buzz

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of $30.0...

Scotiabank Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating yesterday. Graig Suvannavejh ha...

Neutral Stance on Apellis Pharmaceuticals Amid Competitive Uncertainties and Market Stability

Morgan Stanley analyst Judah Frommer initiated coverage of Apellis (APLS) with an Equal Weight rating and $31 price target The firm expects a "roug...

Apellis initiated with an Equal Weight at Morgan Stanley

Apellis Pharmaceuticals (APLS) has received a new Hold rating, initiated by Morgan Stanley analyst, Judah Frommer. Judah Frommer's rating is based ...

Hold Rating for Apellis Pharmaceuticals Amid Market Uncertainties and Competitive Pressures

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Ulta Beauty downgraded, Palo Alto upgraded: Wall Street's top analyst calls

Apellis started at equal-weight at Morgan Stanley on geographic atrophy market

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AAPL

ACRS

ADNT

AKTX

ALPMF

ALPMY

AMZN

APVO

BERY

BLNK

BNTX

CART

CHPT

CHRS

EVTC

GOOG

GOOGL

HOTH

IIIV

INCY

INTC

JNPR

ONON

PANW

SABR

SNEJF

SONY

TNXP

UBER

ULTA

UMBF

VERA

XCUR

XPEV

Legal

Press Releases

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Axonis Therapeutics Announces $115 Million Series A Financing

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

Comments

Apellis Pharmaceuticals

Vendite allo scoperto

Apellis Pharmaceuticals (NASDAQ:APLS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO